195 related articles for article (PubMed ID: 35347578)
1. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
Rosario PW; Mourão GF
Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
[TBL] [Abstract][Full Text] [Related]
2. Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?
Rosario PW; Mourão GF; Calsolari MR
Endocrine; 2020 Dec; 70(3):552-557. PubMed ID: 32653994
[TBL] [Abstract][Full Text] [Related]
3. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
4. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
Ramos da Silva F; Rosario PW; Mourão GF
Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
[TBL] [Abstract][Full Text] [Related]
5. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
6. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract][Full Text] [Related]
7. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
Tian T; Kou Y; Huang R; Liu B
Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
[TBL] [Abstract][Full Text] [Related]
8. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
9. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
Furtado Mde S; Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
[TBL] [Abstract][Full Text] [Related]
10. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
12. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
[TBL] [Abstract][Full Text] [Related]
13. Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.
Rosario PW; Mourão G; Calsolari MR
J Endocrinol Invest; 2019 Jun; 42(6):687-692. PubMed ID: 30353424
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Oct; 37(10):1024-9. PubMed ID: 27306852
[TBL] [Abstract][Full Text] [Related]
16. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
Mourão GF; Rosario PW; Calsolari MR
Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
[TBL] [Abstract][Full Text] [Related]
17. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
[TBL] [Abstract][Full Text] [Related]
18. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
[TBL] [Abstract][Full Text] [Related]
19. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
20. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
